Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has reported that the FDA has accepted for review a new drug application for the use of lacosamide in the treatment of adults with diabetic neuropathic pain.
Subscribe to our email newsletter
In placebo-controlled clinical trials of over 800 people with diabetic neuropathic pain, significant and sustained reductions in pain scores were seen versus placebo.
A similar filing made to the European Medicines Agency in 2007 for the use of lacosamide in the treatment of diabetic neuropathic pain, was also accepted and is currently under review.
Iris Loew-Friedrich, global head of development, UCB, said: “The FDA acceptance for review means that a full assessment will be carried out on lacosamide’s potential to provide sustained pain relief in patients with moderate to severe diabetic neuropathic pain.”